Find an abstract and a link to most of the publications produced by Nordic Bioscience
Objective: Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Ind...
May 27, 2021
Mozes EF, Lee AJ, Selvaraj AE, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber ER, Younes R, Gaia S, Lupsor-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Eddowes PJ, Hirschfield MG, Newsome NP, Wong Wai-Sun V, Chan Wah-Keong, de Ledinghen V, Fan J, Shen F, Cobbold FJ, Kim W, Lee SM, Wiegand J, Karlas T, Yilmaz Y, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi JG, Nakajima A, Yoneda M, Ziol M, Barget N, Geier A, Tuthill T, Brosnan JM, Anstee MQ, Neubauer S, Harrison AS, Bossuyt MP, Pavlides M, Aithal GP, Bugianessi E
Background: Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD); no approved therapies for NASH currently exist. Pegbelfermin (PGBF), a human fibroblast growth factor 21 analog, has metabolic effects that may provide benefit for patients with NASH....